Efficacy of garenoxacin in patients with macrolide-resistant Mycoplasma pneumoniae pneumonia
Naoyuki Miyashita, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Tomoki Ito · 2026
Read Efficacy of garenoxacin in patients with macrolide-resistant Mycoplasma pneumoniae pneumonia by Naoyuki Miyashita, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Tomoki Ito (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13321794.txt.
Description
Naoyuki Miyashita and colleagues compare two antibiotics for drug resistant lung infection in a 2026 short study from Japan. Macrolide resistant Mycoplasma pneumoniae is rising again in Japan, and minocycline is the advised first choice drug. The team tested whether the quinolone garenoxacin works as well for pneumonia caused by resistant strains.
Fever cleared within 48 hours of starting antibiotics in 90.6 percent of garenoxacin patients and 90 percent of minocycline patients in the study. Those near equal results led the authors to propose garenoxacin as a first choice option as well. A further choice matters for clinics facing resistant infections where standard macrolide drugs no longer work.
Catalog record
| CREATOR | Naoyuki Miyashita, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Tomoki Ito |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10145 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |